{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:05:54Z","timestamp":1792058754351,"version":"4.4.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The equity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptability, appropriateness of delivering on-label 2-monthly cabotegravir and rilpivirine (CAB + RPV) injections for human immunodeficiency virus (HIV)-1 therapy in clinics and community settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study, which mandated inclusive recruitment, was conducted May\u2013December 2022 at 6 UK sites. Injections were delivered in clinic (month [M] 1\u20136) and in clinic or community setting according to patient choice (M6\u201312). Surveys were completed at baseline, M4, and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM \u22654) at M12. Fourteen participants completed interviews at baseline and M12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Community settings offered by sites included: home visits (n = 3), HIV support organizations (n = 2), and community clinic (n = 1). Of 114 participants, 54% were female, 70% racially minoritized, and 40% aged \u226550 years. A total of 27\/114 chose to receive injections in community settings. FIM\/AIM\/IAM scores at M12 were high for the injection (79.0\u201387.4%) and lower for the community setting (44.2\u201347.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM\/AIM\/IAM scores for the community setting at M12 were high (73.1\u201380.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAB + RPV injections were considered highly feasible, acceptable, and appropriate; however, few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov<\/jats:title>\n                    <jats:p>NCT05294159<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae523","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:23:32Z","timestamp":1729783412000},"page":"1103-1113","source":"Crossref","is-referenced-by-count":18,"title":["Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"SHARE Collaborative, Blizard Institute, Queen Mary University of London , London ,","place":["United Kingdom"]},{"name":"HIV\/GUM Directorate, Barts Health NHS Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-4101","authenticated-orcid":false,"given":"Rosalie","family":"Hayes","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Wolfson Institute of Population Health, Queen Mary University of London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-3636","authenticated-orcid":false,"given":"Joanne","family":"Haviland","sequence":"additional","affiliation":[{"name":"Pragmatic Clinical Trials Unit, Wolfson Institute of Population Health, Queen Mary University of London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7235","authenticated-orcid":false,"given":"Yuk Lam","family":"Wong","sequence":"additional","affiliation":[{"name":"Pragmatic Clinical Trials Unit, Wolfson Institute of Population Health, Queen Mary University of London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-4643","authenticated-orcid":false,"given":"Kyle","family":"Ring","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Blizard Institute, Queen Mary University of London , London ,","place":["United Kingdom"]},{"name":"HIV\/GUM Directorate, Barts Health NHS Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-8292","authenticated-orcid":false,"given":"Vanessa","family":"Apea","sequence":"additional","affiliation":[{"name":"HIV\/GUM Directorate, Barts Health NHS Trust , London ,","place":["United Kingdom"]},{"name":"SHARE Collaborative, Wolfson Institute of Population Health, Queen Mary University of London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2862-183X","authenticated-orcid":false,"given":"Bakita","family":"Kasadha","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-1417","authenticated-orcid":false,"given":"Emily","family":"Clarke","sequence":"additional","affiliation":[{"name":"Axess Sexual Health, Liverpool University Hospitals NHS Foundation Trust , Liverpool ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Byrne","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s Centre, Chelsea and Westminster Hospital NHS Foundation Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-8019","authenticated-orcid":false,"given":"Julie","family":"Fox","sequence":"additional","affiliation":[{"name":"School of Immunology & Microbial Sciences, Kings College London , London ,","place":["United Kingdom"]},{"name":"Infection and Immunity, Guy's and St Thomas\u2019 NHS Foundation Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-4891","authenticated-orcid":false,"given":"Tristan J","family":"Barber","sequence":"additional","affiliation":[{"name":"Ian Charleson Day Centre, Royal Free London NHS Foundation Trust , London ,","place":["United Kingdom"]},{"name":"Institute for Global Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-2035","authenticated-orcid":false,"given":"Amanda","family":"Clarke","sequence":"additional","affiliation":[{"name":"The Lawson Unit, University Hospitals Sussex NHS Foundation Trust , Brighton ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-2481","authenticated-orcid":false,"given":"Sara","family":"Paparini","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Wolfson Institute of Population Health, Queen Mary University of London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"2025060412013725600_ciae523-B1","author":"European AIDS Clinical Society (EACS)"},{"issue":"Suppl. 5","key":"2025060412013725600_ciae523-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13446","article-title":"BHIVA guidelines on antiretroviral treatment for adults living with HIV-1","volume":"23","author":"Waters","year":"2022","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025060412013725600_ciae523-B4","doi-asserted-by":"crossref","first-page":"e26003","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a hybrid III implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025060412013725600_ciae523-B5","first-page":"20","article-title":"Perceptions of cabotegravir and rilpivirine long-acting (CAB+RPV LA) from patients in the CAB+RPV implementation study in European locations (CARISEL)","volume":"24","author":"Lutz","year":"2023","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B6","first-page":"99","article-title":"Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir + rilpivirine long-acting injectable treatment (CAB+RPV LA): interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)","volume":"22","author":"Hocqueloux","year":"2021","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B7","first-page":"22","article-title":"Initiating CAB + RPV LA in a real-world setting\u2014clinical characteristics and switch reasons from PLHIV and HCP perspectives in the German CARLOS cohort","volume":"24","author":"Wyen","year":"2023","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B8"},{"key":"2025060412013725600_ciae523-B9","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/ofid\/ofac492.105","article-title":"Real-world use of long-acting cabotegravir + rilpivirine in the US: effectiveness in the first year","volume":"9","author":"Sension","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025060412013725600_ciae523-B10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)","volume":"25","author":"Ring","year":"2024","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B11","doi-asserted-by":"crossref","first-page":"S553","DOI":"10.1093\/ofid\/ofac492.1119","article-title":"US healthcare provider perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)","volume":"9","author":"Hsu","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025060412013725600_ciae523-B12","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2025060412013725600_ciae523-B13","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025060412013725600_ciae523-B14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2025060412013725600_ciae523-B15","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"key":"2025060412013725600_ciae523-B16","author":"Elias"},{"key":"2025060412013725600_ciae523-B17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(22)01972-9","article-title":"Racism, xenophobia, discrimination, and the determination of health","volume":"400","author":"Devakumar","year":"2022","journal-title":"Lancet"},{"key":"2025060412013725600_ciae523-B18","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/S0140-6736(19)30985-7","article-title":"Why now for a series on gender equality, norms, and health?","volume":"393","author":"Darmstadt","year":"2019","journal-title":"Lancet"},{"key":"2025060412013725600_ciae523-B19","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(23)00226-6","article-title":"Ageism: the -ism affecting the lives of older people living with HIV","volume":"11","author":"Guaraldi","year":"2024","journal-title":"Lancet HIV"},{"key":"2025060412013725600_ciae523-B20","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMp2008628","article-title":"Understanding and mitigating health inequities\u2014past, current, and future directions","volume":"384","author":"Lavizzo-Mourey","year":"2021","journal-title":"N Engl J Med"},{"key":"2025060412013725600_ciae523-B21","doi-asserted-by":"crossref","first-page":"e034793","DOI":"10.1136\/bmjopen-2019-034793","article-title":"Overview of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral therapy and retention in care for people living with HIV: part 1","volume":"10","author":"Mbuagbaw","year":"2020","journal-title":"BMJ Open"},{"key":"2025060412013725600_ciae523-B22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/COH.0000000000000723","article-title":"Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV","volume":"17","author":"Philbin","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2025060412013725600_ciae523-B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/aid.2020.0126","article-title":"The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review","volume":"37","author":"Kanazawa","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025060412013725600_ciae523-B24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/apc.2023.0154","article-title":"Receipt of injectable HIV treatment in clinic versus at home: perspectives of persons living with HIV infection","volume":"37","author":"Adekunle","year":"2023","journal-title":"AIDS Patient Care STDs"},{"key":"2025060412013725600_ciae523-B25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12954-023-00730-z","article-title":"Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and\/or housing instability","volume":"20","author":"Fletcher","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025060412013725600_ciae523-B26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","article-title":"Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials","volume":"21","author":"Mantsios","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025060412013725600_ciae523-B27","doi-asserted-by":"crossref","first-page":"ofae265","DOI":"10.1093\/ofid\/ofae265","article-title":"Patient attitudes toward self- or partner-, friend-, or family-administered long-acting injectable antiretroviral therapy: a mixed-methods study across 3 urban human immunodeficiency virus clinics","volume":"11","author":"Collins","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025060412013725600_ciae523-B28","author":"Roucoux"},{"key":"2025060412013725600_ciae523-B29","author":"Williams"},{"key":"2025060412013725600_ciae523-B30","doi-asserted-by":"crossref","first-page":"e070666","DOI":"10.1136\/bmjopen-2022-070666","article-title":"Study protocol: the ILANA study\u2014exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK\u2014a qualitative multiphase longitudinal study design","volume":"13","author":"Farooq","year":"2023","journal-title":"BMJ Open"},{"key":"2025060412013725600_ciae523-B31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"2025060412013725600_ciae523-B32","author":"Eu"},{"key":"2025060412013725600_ciae523-B33","first-page":"21","article-title":"P017 what influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA trial","volume":"24","author":"Hayes","year":"2023","journal-title":"HIV Med"},{"key":"2025060412013725600_ciae523-B34","author":"Paparini"},{"key":"2025060412013725600_ciae523-B35","author":"United Kingdom Health Security Agency (UKHSA)"},{"key":"2025060412013725600_ciae523-B36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025060412013725600_ciae523-B37","author":"Rana"},{"key":"2025060412013725600_ciae523-B38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/apc.2024.0048","article-title":"Long-acting injectable ART in practice: a mixed methods implementation study assessing the feasibility of using LAI ART in high risk populations and at alternative low barrier care sites","volume":"38","author":"Fletcher","year":"2024","journal-title":"AIDS Patient Care STDs"},{"key":"2025060412013725600_ciae523-B39","author":"Department of Health and Social Care"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae523\/60139535\/ciae523.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/1103\/60139535\/ciae523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/1103\/60139535\/ciae523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:01:50Z","timestamp":1749038510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/5\/1103\/7846271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae523","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2024,10,28]]}}}